Publications 2018

Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, Berge KE, Edvardsen T, Haugaa KH (2018)
Vigorous exercise in patients with hypertrophic cardiomyopathy
Int J Cardiol, 250, 157-163
DOI 10.1016/j.ijcard.2017.07.015, PubMed 29169752

Hasselberg NE, Berge KE, Rasmussen M, Früh A, Ørstavik K, Haugaa KH (2018)
[Cardiomyopathy in hereditary muscular dystrophies]
Tidsskr Nor Laegeforen, 138 (1)
DOI 10.4045/tidsskr.16.0683, PubMed 29313627

Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, Edvardsen T, Haugaa KH (2018)
Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation
Eur Heart J, 39 (10), 853-860
DOI 10.1093/eurheartj/ehx596, PubMed 29095976

Publications 2017

Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, Berge KE, Edvardsen T, Haugaa KH (2017)
Data on exercise and cardiac imaging in a patient cohort with hypertrophic cardiomyopathy
Data Brief, 15, 30-39
DOI 10.1016/j.dib.2017.08.018, PubMed 28971120

Haland TF, Hasselberg NE, Almaas VM, Dejgaard LA, Saberniak J, Leren IS, Berge KE, Haugaa KH, Edvardsen T (2017)
The systolic paradox in hypertrophic cardiomyopathy
Open Heart, 4 (1), e000571
DOI 10.1136/openhrt-2016-000571, PubMed 28674623

Hatlen B, Berge K, Nordrum S, Johnsen K, Kolstad K, Morkore T (2017)
The effect of low inclusion levels of Antarctic krill (Euphausia superba) meal on growth performance, apparent digestibility and slaughter quality of Atlantic salmon (Salmo salar)
Aquac. Nutr., 23 (4), 721-729

Retterstøl K, Narverud I, Selmer R, Berge KE, Osnes IV, Ulven SM, Halvorsen B, Aukrust P, Holven KB, Iversen PO (2017)
Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics
Lipids Health Dis, 16 (1), 115
DOI 10.1186/s12944-017-0511-9, PubMed 28606150

Subasinghe CJ, Sirisena ND, Herath C, Berge KE, Leren TP, Bulugahapitiya U, Dissanayake VHW (2017)
Novel mutation in the SLC12A3 gene in a Sri Lankan family with Gitelman syndrome & coexistent diabetes: a case report
BMC Nephrol, 18 (1), 140
DOI 10.1186/s12882-017-0563-0, PubMed 28446151

Publications 2016

Leren TP, Strøm TB, Berge KE (2016)
Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene
Mol Genet Metab Rep, 9, 67-70
DOI 10.1016/j.ymgmr.2016.10.007, PubMed 27830118

Pingitore P, Lepore SM, Pirazzi C, Mancina RM, Motta BM, Valenti L, Berge KE, Retterstøl K, Leren TP, Wiklund O, Romeo S (2016)
Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia
J Clin Lipidol, 10 (4), 816-823
DOI 10.1016/j.jacl.2016.02.015, PubMed 27578112

van der Wurff IS, von Schacky C, Berge K, Kirschner PA, de Groot RH (2016)
A protocol for a randomised controlled trial investigating the effect of increasing Omega-3 index with krill oil supplementation on learning, cognition, behaviour and visual processing in typically developing adolescents
BMJ Open, 6 (7), e011790
DOI 10.1136/bmjopen-2016-011790, PubMed 27401364

Yu H, Zhang VW, Stray-Pedersen A, Hanson IC, Forbes LR, de la Morena MT, Chinn IK, Gorman E, Mendelsohn NJ, Pozos T, Wiszniewski W, Nicholas SK, Yates AB, Moore LE, Berge KE, Sorte H, Bayer DK, ALZahrani D, Geha RS, Feng Y, Wang G, Orange JS, Lupski JR, Wang J, Wong LJ (2016)
Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing
J Allergy Clin Immunol, 138 (4), 1142-1151.e2
DOI 10.1016/j.jaci.2016.05.035, PubMed 27484032

Publications 2014

Berge KE, Retterstøl K, Romeo S, Pirazzi C, Leren TP (2014)
Type 1 hyperlipoproteinemia due to a novel deletion of exons 3 and 4 in the GPIHBP1 gene
Atherosclerosis, 234 (1), 30-3
DOI 10.1016/j.atherosclerosis.2014.02.005, PubMed 24589565

Publications 2013

Berge KE, Leren TP (2013)
Genetics of hypertrophic cardiomyopathy in Norway
Clin Genet, 86 (4), 355-60
DOI 10.1111/cge.12286, PubMed 24111713

Hasselberg NE, Edvardsen T, Petri H, Berge KE, Leren TP, Bundgaard H, Haugaa KH (2013)
Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects
Europace, 16 (4), 563-71
DOI 10.1093/europace/eut291, PubMed 24058181

Holven KB, Retterstøl K, Ueland T, Ulven SM, Nenseter MS, Sandvik M, Narverud I, Berge KE, Ose L, Aukrust P, Halvorsen B (2013)
Subjects with low plasma HDL cholesterol levels are characterized by an inflammatory and oxidative phenotype
PLoS One, 8 (11), e78241
DOI 10.1371/journal.pone.0078241, PubMed 24244297

Tveten K, Strøm TB, Berge KE, Leren TP (2013)
PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment
J Lipid Res, 54 (6), 1560-6
DOI 10.1194/jlr.M034371, PubMed 23509406

Publications 2012

Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP (2012)
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways
Transl Res, 160 (2), 125-30
DOI 10.1016/j.trsl.2012.01.010, PubMed 22683370

Larsen MK, Berge KE, Leren TP, Nissen PH, Hansen J, Kristensen IB, Banner J, Jensen HK (2012)
Postmortem genetic testing of the ryanodine receptor 2 (RYR2) gene in a cohort of sudden unexplained death cases
Int J Legal Med, 127 (1), 139-44
DOI 10.1007/s00414-011-0658-2, PubMed 22222782

Tveten K, Strøm TB, Cameron J, Berge KE, Leren TP (2012)
Mutations in the SORT1 gene are unlikely to cause autosomal dominant hypercholesterolemia
Atherosclerosis, 225 (2), 370-5
DOI 10.1016/j.atherosclerosis.2012.10.026, PubMed 23102784

Winkel BG, Larsen MK, Berge KE, Leren TP, Nissen PH, Olesen MS, Hollegaard MV, Jespersen T, Yuan L, Nielsen N, Haunsø S, Svendsen JH, Wang Y, Kristensen IB, Jensen HK, Tfelt-Hansen J, Banner J (2012)
The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases
J Cardiovasc Electrophysiol, 23 (10), 1092-8
DOI 10.1111/j.1540-8167.2012.02371.x, PubMed 22882672

Publications 2011

Holla ØL, Cameron J, Tveten K, Strøm TB, Berge KE, Laerdahl JK, Leren TP (2011)
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
J Lipid Res, 52 (10), 1787-94
DOI 10.1194/jlr.M018093, PubMed 21771976

Holla ØL, Laerdahl JK, Strøm TB, Tveten K, Cameron J, Berge KE, Leren TP (2011)
Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor
Biochem Biophys Res Commun, 406 (2), 234-8
DOI 10.1016/j.bbrc.2011.02.023, PubMed 21324305

Larsen MK, Nissen PH, Berge KE, Leren TP, Kristensen IB, Jensen HK, Banner J (2011)
Molecular autopsy in young sudden cardiac death victims with suspected cardiomyopathy
Forensic Sci Int, 219 (1-3), 33-8
DOI 10.1016/j.forsciint.2011.11.020, PubMed 22177269

Leren TP, Berge KE (2011)
Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated
PLoS One, 6 (2), e16721
DOI 10.1371/journal.pone.0016721, PubMed 21364743

Mousavi SA, Berge KE, Berg T, Leren TP (2011)
Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells
FEBS J, 278 (16), 2938-50
DOI 10.1111/j.1742-4658.2011.08219.x, PubMed 21692990

Strøm TB, Tveten K, Holla ØL, Cameron J, Berge KE, Leren TP (2011)
The cytoplasmic domain is not involved in directing Class 5 mutant LDL receptors to lysosomal degradation
Biochem Biophys Res Commun, 408 (4), 642-6
DOI 10.1016/j.bbrc.2011.04.077, PubMed 21531209

Strøm TB, Tveten K, Holla ØL, Cameron J, Berge KE, Leren TP (2011)
Characterization of residues in the cytoplasmic domain of the LDL receptor required for exit from the endoplasmic reticulum
Biochem Biophys Res Commun, 415 (4), 642-5
DOI 10.1016/j.bbrc.2011.10.127, PubMed 22079632

Tveten K, Holla ØL, Cameron J, Strøm TB, Berge KE, Laerdahl JK, Leren TP (2011)
Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification
Hum Mol Genet, 21 (6), 1402-9
DOI 10.1093/hmg/ddr578, PubMed 22156580

Tveten K, Strøm TB, Cameron J, Holla ØL, Berge KE, Leren TP (2011)
Characterization of a naturally occurring degradation product of the LDL receptor
Mol Genet Metab, 105 (1), 149-54
DOI 10.1016/j.ymgme.2011.10.008, PubMed 22078455

Publications 2010

Berge KE, Leren TP (2010)
Mutations in APOA-I and ABCA1 in Norwegians with low levels of HDL cholesterol
Clin Chim Acta, 411 (23-24), 2019-23
DOI 10.1016/j.cca.2010.08.027, PubMed 20800056

Haugaa KH, Amlie JP, Berge KE, Leren TP, Smiseth OA, Edvardsen T (2010)
Transmural differences in myocardial contraction in long-QT syndrome: mechanical consequences of ion channel dysfunction
Circulation, 122 (14), 1355-63
DOI 10.1161/CIRCULATIONAHA.110.960377, PubMed 20855658

Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, Früh A, Edvardsen T, Kongsgård E, Leren TP, Amlie JP (2010)
High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening
Europace, 12 (3), 417-23
DOI 10.1093/europace/eup448, PubMed 20106799

Kulseth MA, Berge KE, Bogsrud MP, Leren TP (2010)
Analysis of LDLR mRNA in patients with familial hypercholesterolemia revealed a novel mutation in intron 14, which activates a cryptic splice site
J Hum Genet, 55 (10), 676-80
DOI 10.1038/jhg.2010.87, PubMed 20703241

Leren IS, Haugaa KH, Edvardsen T, Anfinsen OG, Kongsgård E, Berge KE, Leren TP, Amlie JP (2010)
[Catecholaminergic polymorphic ventricular tachycardia]
Tidsskr Nor Laegeforen, 130 (2), 139-42
DOI 10.4045/tidsskr.09.0529, PubMed 20125202

Strøm TB, Holla ØL, Tveten K, Cameron J, Berge KE, Leren TP (2010)
Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain
Mol Genet Metab, 101 (1), 76-80
DOI 10.1016/j.ymgme.2010.05.003, PubMed 20659812

Tandy S, Chung RWS, Wat E, Kamili A, Griinari M, Berge K, Cohn JS (2010)
Dietary krill oil significantly reduces hepatic steatosis, glycaemia and hypercholesterolaemia in high-fat-fed mice
Proc. Nutr. Soc., 69 (OCE1), E48

Publications 2009

Cameron J, Holla ØL, Kulseth MA, Leren TP, Berge KE (2009)
Splice-site mutation c.313+1, G>A in intron 3 of the LDL receptor gene results in transcripts with skipping of exon 3 and inclusion of intron 3
Clin Chim Acta, 403 (1-2), 131-5
DOI 10.1016/j.cca.2009.02.001, PubMed 19361455

Cameron J, Ranheim T, Halvorsen B, Kulseth MA, Leren TP, Berge KE (2009)
Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532C
Atherosclerosis, 209 (1), 163-6
DOI 10.1016/j.atherosclerosis.2009.08.039, PubMed 19765707

Holla ØL, Kulseth MA, Berge KE, Leren TP, Ranheim T (2009)
Nonsense-mediated decay of human LDL receptor mRNA
Scand J Clin Lab Invest, 69 (3), 409-17
DOI 10.1080/00365510802707163, PubMed 19148831

Holla ØL, Nakken S, Mattingsdal M, Ranheim T, Berge KE, Defesche JC, Leren TP (2009)
Effects of intronic mutations in the LDLR gene on pre-mRNA splicing: Comparison of wet-lab and bioinformatics analyses
Mol Genet Metab, 96 (4), 245-52
DOI 10.1016/j.ymgme.2008.12.014, PubMed 19208450

Holla ØL, Strøm TB, Cameron J, Berge KE, Leren TP (2009)
A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9
Mol Genet Metab, 99 (2), 149-56
DOI 10.1016/j.ymgme.2009.09.012, PubMed 19828345

Leren TP, Berge KE (2009)
Comparison of clinical and molecular genetic criteria for diagnosing familial hypercholesterolemia
Clin. Lipidol., 4 (3), 303-310

Mousavi SA, Berge KE, Leren TP (2009)
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
J Intern Med, 266 (6), 507-19
DOI 10.1111/j.1365-2796.2009.02167.x, PubMed 19930098

Nakken KE, Nygard S, Haaland TK, Berge KE, Ødegaard A, Labori KJ, Raeder MG (2009)
Gene expression profiles reflect sclerosing cholangitis activity in abcb4 (-/-) mice
Scand J Gastroenterol, 44 (2), 211-8
DOI 10.1080/00365520802400867, PubMed 18785065

Strøm TB, Holla ØL, Cameron J, Berge KE, Leren TP (2009)
Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes
Clin Chim Acta, 411 (3-4), 229-33
DOI 10.1016/j.cca.2009.11.008, PubMed 19917273

Tveten K, Khoo KL, Berge KE, Leren TP, Kulseth MA (2009)
Functional analysis of the synonymous R385R mutation in the low-density lipoprotein receptor gene
Genet Test Mol Biomarkers, 13 (2), 243-8
DOI 10.1089/gtmb.2008.0125, PubMed 19371225

Tveten K, Ranheim T, Berge KE, Leren TP, Kulseth MA (2009)
The effect of bafilomycin A1 and protease inhibitors on the degradation and recycling of a Class 5-mutant LDLR
Acta Biochim Biophys Sin (Shanghai), 41 (3), 246-55
DOI 10.1093/abbs/gmp008, PubMed 19280064

Publications 2008

Berge KE, Haugaa KH, Früh A, Anfinsen OG, Gjesdal K, Siem G, Oyen N, Greve G, Carlsson A, Rognum TO, Hallerud M, Kongsgård E, Amlie JP, Leren TP (2008)
Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers
Scand J Clin Lab Invest, 68 (5), 362-8
DOI 10.1080/00365510701765643, PubMed 18752142

Cameron J, Holla OL, Laerdahl JK, Kulseth MA, Ranheim T, Rognes T, Berge KE, Leren TP (2008)
Characterization of novel mutations in the catalytic domain of the PCSK9 gene
J Intern Med, 263 (4), 420-31
DOI 10.1111/j.1365-2796.2007.01915.x, PubMed 18266662

Cameron J, Holla ØL, Berge KE, Kulseth MA, Ranheim T, Leren TP, Laerdahl JK (2008)
Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion
FEBS J, 275 (16), 4121-33
DOI 10.1111/j.1742-4658.2008.06553.x, PubMed 18631360

Cameron J, Holla ØL, Laerdahl JK, Kulseth MA, Berge KE, Leren TP (2008)
Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage
Atherosclerosis, 203 (1), 161-5
DOI 10.1016/j.atherosclerosis.2008.10.007, PubMed 19022446

Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE (2008)
Berberine decreases PCSK9 expression in HepG2 cells
Atherosclerosis, 201 (2), 266-73
DOI 10.1016/j.atherosclerosis.2008.02.004, PubMed 18355829

Leren TP, Berge KE (2008)
Identification of mutations in the apolipoprotein B-100 gene and in the PCSK9 gene as the cause of hypocholesterolemia
Clin Chim Acta, 397 (1-2), 92-5
DOI 10.1016/j.cca.2008.07.025, PubMed 18710658

Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE (2008)
Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening
Community Genet, 11 (1), 26-35
DOI 10.1159/000111637, PubMed 18196915

Nakken KE, Labori KJ, Rødningen OK, Nakken S, Berge KE, Eiklid K, Raeder MG (2008)
ABCB4 sequence variations in young adults with cholesterol gallstone disease
Liver Int, 29 (5), 743-7
DOI 10.1111/j.1478-3231.2008.01914.x, PubMed 19018976

Ranheim T, Mattingsdal M, Lindvall JM, Holla OL, Berge KE, Kulseth MA, Leren TP (2008)
Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9
J Cell Physiol, 217 (2), 459-67
DOI 10.1002/jcp.21519, PubMed 18570182

Publications 2007

Djurovic S, Berge KE, Birkenes B, Braaten Ø, Retterstøl L (2007)
The effect of red wine on plasma leptin levels and vasoactive factors from adipose tissue: a randomized crossover trial
Alcohol Alcohol, 42 (6), 525-8
DOI 10.1093/alcalc/agm056, PubMed 17670801

Holla ØL, Cameron J, Berge KE, Ranheim T, Leren TP (2007)
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
BMC Cell Biol, 8, 9
DOI 10.1186/1471-2121-8-9, PubMed 17328821

Leren TP, Manshaus TE, Ose L, Berge KE (2007)
[Lipid profile in children and adolescents with familial hypercholesterolemia]
Tidsskr Nor Laegeforen, 127 (18), 2363-6
PubMed 17895939

Nakken KE, Nygård S, Haaland T, Berge KE, Arnkvaern K, Ødegaard A, Labori KJ, Raeder MG (2007)
Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/ - ) mice harbouring chronic cholangitis
Scand J Gastroenterol, 42 (10), 1245-55
DOI 10.1080/00365520701320521, PubMed 17852852

Tveten K, Holla ØL, Ranheim T, Berge KE, Leren TP, Kulseth MA (2007)
4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor
FEBS J, 274 (8), 1881-93
DOI 10.1111/j.1742-4658.2007.05735.x, PubMed 17408384

Publications 2006

Berge KE, Ose L, Leren TP (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
Arterioscler Thromb Vasc Biol, 26 (5), 1094-100
DOI 10.1161/01.ATV.0000204337.81286.1c, PubMed 16424354

Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, Leren TP (2006)
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
Hum Mol Genet, 15 (9), 1551-8
DOI 10.1093/hmg/ddl077, PubMed 16571601

Holla ØL, Cameron J, Berge KE, Kulseth MA, Ranheim T, Leren TP (2006)
Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene
Scand J Clin Lab Invest, 66 (4), 317-28
DOI 10.1080/00365510600672775, PubMed 16777760

Ranheim T, Kulseth MA, Berge KE, Leren TP (2006)
Model system for phenotypic characterization of sequence variations in the LDL receptor gene
Clin Chem, 52 (8), 1469-79
DOI 10.1373/clinchem.2006.068627, PubMed 16740646

Tveten K, Ranheim T, Berge KE, Leren TP, Kulseth MA (2006)
Analysis of alternatively spliced isoforms of human LDL receptor mRNA
Clin Chim Acta, 373 (1-2), 151-7
DOI 10.1016/j.cca.2006.05.031, PubMed 16828075

Publications 2005

Berge KE, Haugaa KH, Anfinsen OG, Früh A, Hallerud M, Jonsrud C, Øyen N, Gjesdal K, Amlie JP, Leren TP (2005)
[DNA-based diagnostics of long QT syndrome]
Tidsskr Nor Laegeforen, 125 (20), 2783-6
PubMed 16244680

Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA, Skorve J (2005)
The metabolic syndrome and the hepatic fatty acid drainage hypothesis
Biochimie, 87 (1), 15-20
DOI 10.1016/j.biochi.2004.11.011, PubMed 15733731

Haugaa KH, Berge KE, Früh A, Anfinsen OG, Arnestad M, Hallerud M, Gjesdal K, Leren TP, Amlie JP (2005)
[Cardiac ion channel disorders--diagnosis and treatment]
Tidsskr Nor Laegeforen, 125 (20), 2778-81
PubMed 16244679

Holla Ø, Teie C, Berge KE, Leren TP (2005)
Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA
Clin Chim Acta, 356 (1-2), 164-71
DOI 10.1016/j.cccn.2005.01.028, PubMed 15936313

Retterstol L, Berge KE, Braaten Ø, Eikvar L, Pedersen TR, Sandvik L (2005)
A daily glass of red wine: does it affect markers of inflammation?
Alcohol Alcohol, 40 (2), 102-5
DOI 10.1093/alcalc/agh132, PubMed 15642722

Roussa E, Bertram J, Berge KE, Labori KJ, Thévenod F, Raeder MG (2005)
Differential regulation of vacuolar H+ -ATPase and Na+/H+ exchanger 3 in rat cholangiocytes after bile duct ligation
Histochem Cell Biol, 125 (4), 419-28
DOI 10.1007/s00418-005-0082-0, PubMed 16267653

Publications 2004

Hubácek JA, Berge KE, Stefková J, Pitha J, Skodová Z, Lánská V, Poledne R (2004)
Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels
Physiol Res, 53 (4), 395-401
PubMed 15311998

Publications 2003

Berge KE (2003)
Sitosterolemia: a gateway to new knowledge about cholesterol metabolism
Ann Med, 35 (7), 502-11
DOI 10.1080/07853890310014588, PubMed 14649332

Publications 2002

Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC (2002)
Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8
J Lipid Res, 43 (3), 486-94
PubMed 11893785

Langeggen H, Berge KE, Johnson E, Hetland G (2002)
Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro
Inflammation, 26 (3), 103-10
PubMed 12083416

Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ (2002)
Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta
J Biol Chem, 277 (21), 18793-800
DOI 10.1074/jbc.M109927200, PubMed 11901146

Tronstad KJ, Bruserud Ø, Berge K, Berge RK (2002)
Antiproliferative effects of a non-beta-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures
Leukemia, 16 (11), 2292-301
DOI 10.1038/sj.leu.2402698, PubMed 12399975

Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH (2002)
Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol
J Clin Invest, 110 (5), 671-80
DOI 10.1172/JCI16001, PubMed 12208868

Publications 2001

Berge K (2001)
Studies on the literary history of the Old Testament
J. Biblic. Lit., 120 (3), 532-535

Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K, Berge RK (2001)
Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways
Carcinogenesis, 22 (11), 1747-55
DOI 10.1093/carcin/22.11.1747, PubMed 11698335

Fossum E, Berge KE, Høieggen A, Moan A, Rostrup M, Kjeldsen SE, Eide I, Berg K (2001)
Polymorphisms in candidate genes for blood pressure regulation in young men with normal or elevated screening blood pressure
Blood Press, 10 (2), 92-100
DOI 10.1080/08037050152112078, PubMed 11467765

Hubacek JA, Berge KE, Cohen JC, Hobbs HH (2001)
Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia
Hum Mutat, 18 (4), 359-60
DOI 10.1002/humu.1206, PubMed 11668628

Langeggen H, Berge KE, Macor P, Fischetti F, Tedesco F, Hetland G, Berg K, Johnson E (2001)
Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro
APMIS, 109 (1), 73-8
DOI 10.1111/j.1600-0463.2001.tb00016.x, PubMed 11297196

Tronstad KJ, Berge K, Dyroy E, Madsen L, Berge RK (2001)
Growth reduction in glioma cells after treatment with tetradecylthioacetic acid: changes in fatty acid metabolism and oxidative status
Biochem Pharmacol, 61 (6), 639-49
DOI 10.1016/S0006-2952(01)00525-1, PubMed 11266648

Tronstad KJ, Berge K, Flindt EN, Kristiansen K, Berge RK (2001)
Optimization of methods and treatment conditions for studying effects of fatty acids on cell growth
Lipids, 36 (3), 305-13
DOI 10.1007/s11745-001-0722-8, PubMed 11337987

Publications 2000

Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH (2000)
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters
Science, 290 (5497), 1771-5
PubMed 11099417

Publications 1999

Berge K, Tronstad KJ, Abdi-Dezfuli F, Ranheim T, Mahesparan R, Bjerkvig R, Berge RK (1999)
Poorly oxidizable fatty acid analogues inhibit the proliferation of cancer cells in culture
Adv Exp Med Biol, 466, 205-10
PubMed 10709646

Madsen L, Rustan AC, Vaagenes H, Berge K, Dyrøy E, Berge RK (1999)
Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference
Lipids, 34 (9), 951-63
DOI 10.1007/s11745-999-0445-x, PubMed 10574660

Tronstad KJ, Berge K, Bjerkvig R, Flatmark T, Berge RK (1999)
Metabolic effects of 3-thia fatty acid in cancer cells
Adv Exp Med Biol, 466, 201-4
PubMed 10709645

Publications 1998

Berge KE, Berg K (1998)
Polymorphisms at the angiotensinogen (AGT) and angiotensin II type 1 receptor (AT1R) loci and normal blood pressure
Clin Genet, 53 (3), 214-9
PubMed 9630078

Publications 1997

Berge KE, Bakken A, Bøhn M, Erikssen J, Berg K (1997)
A DNA polymorphism at the angiotensin II type 1 receptor (AT1R) locus and myocardial infarction
Clin Genet, 52 (2), 71-6
PubMed 9298740

Berge KE, Bakken A, Bøhn M, Erikssen J, Berg K (1997)
Analyses of mutations in the human renal kallikrein (hKLK1) gene and their possible relevance to blood pressure regulation and risk of myocardial infarction
Clin Genet, 52 (2), 86-95
PubMed 9298743

Berge KE, Berg K (1997)
Cardiovascular risk factors in people with different genotypes in the insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme (ACE)
Clin Genet, 52 (6), 422-6
PubMed 9520252

Berge KE, Djurovic S, Muller HJ, Alestrøm P, Berg K (1997)
Studies on effects of Lp(a) lipoprotein on gene expression in endothelial cells in vitro
Clin Genet, 52 (5), 314-25
PubMed 9520122

Publications 1996

Berge V, Berge KE, Johnson E (1996)
Vitronectin modulates the expression of complement components of the terminal pathway synthesized by human umbilical vein endothelial cells in vitro
APMIS, 104 (7-8), 523-30
DOI 10.1111/j.1699-0463.1996.tb04907.x, PubMed 8920805

Berge V, Johnson E, Berge KE (1996)
Interleukin-1 alpha, interleukin 6 and tumor necrosis factor alpha increase the synthesis and expression of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro
APMIS, 104 (3), 213-9
PubMed 8611196

Wassertheil-Smoller S, Applegate WB, Berge K, Chang CJ, Davis BR, Grimm R, Kostis J, Pressel S, Schron E (1996)
Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systoloc Hypertension in the elderly)
Arch Intern Med, 156 (5), 553-61
PubMed 8604962

Publications 1994

Berge KE, Berg K (1994)
No effect of a BglI polymorphism at the renin (REN) locus on blood pressure level or variability
Clin Genet, 46 (6), 436-8
PubMed 7889662

Berge KE, Berg K (1994)
No effect on blood pressure level or variability of polymorphisms in DNA at the locus for atrial natriuretic factor (ANF)
Clin Genet, 46 (6), 433-5
PubMed 7889661

Berge KE, Berg K (1994)
No effect of insertion/deletion polymorphism at the ACE locus on normal blood pressure level or variability
Clin Genet, 45 (4), 169-74
PubMed 8062433

Berge KE, Bøhn M, Berg K (1994)
DNA polymorphism at the locus for angiotensinogen I-converting enzyme in Norwegian patients with myocardial infarction and controls
Clin Genet, 46 (1 Spec No), 102-4
PubMed 7988066

Publications 1993

Berge KE, Berg K (1993)
No effect of TaqI polymorphism at the human renal kallikrein (KLK1) locus on normal blood pressure level or variability
Clin Genet, 44 (4), 196-202
PubMed 7903227

Bøhn M, Berge KE, Bakken A, Erikssen J, Berg K (1993)
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction
Clin Genet, 44 (6), 292-7
PubMed 8131299

Bøhn M, Berge KE, Bakken A, Erikssen J, Berg K (1993)
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction
Clin Genet, 44 (6), 298-301
PubMed 8131300

Kanazi G, Plevak D, Rakela J, Marin E, Berge K, Piepgras D (1993)
How helpful is intracranial pressure monitoring in patients with acute hepatic failure?
Transplant Proc, 25 (2), 1819
PubMed 8470178

Publications 1992

Berge KE, Berg K (1992)
No effect of a Taq1 polymorphism in DNA at the endothelin I (EDN1) locus on normal blood pressure level or variability
Clin Genet, 41 (2), 90-5
PubMed 1347490

Publications 1991

Berge KE, Berg K (1991)
A TaqI RFLP at the human renal kallikrein (KLK1) locus
Clin Genet, 40 (3), 256
PubMed 1685360

Wittes J, Davis B, Berge K, Cohen JD, Grimm RH, Hawkins CM, Kuller L (1991)
Systolic Hypertension of the Elderly Program (SHEP). Part 10: Analysis
Hypertension, 17 (3 Suppl), II162-7
PubMed 1999372

Publications 1990

Berge KE, Berg K (1990)
A TaqI RFLP at the EDN1 gene locus
Nucleic Acids Res, 18 (20), 6176
DOI 10.1093/nar/18.20.6176-a, PubMed 1978292

Publications 1951

HALBERG F, VISSCHER MB, FLINK EB, BERGE K, BOCK F (1951)
Diurnal rhythmic changes in blood eosinophil levels in health and in certain diseases
J Lancet, 71 (8), 312-9
PubMed 14861536